Development of a policy model for pediatric acute lymphoblastic leukemia to facilitate economic evaluation
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djaf024 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Petros Pechlivanoglou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON M5G0A4, Canada. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Models, Economic, Risk Assessment, Health Policy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Government of Ontario Early Research Award.
Abstract (Originalsprache)
Background
New highly effective, but expensive, immunotherapies have revolutionized the treatment of relapsed pediatric acute lymphoblastic leukemia (ALL) but their long-term clinical and economic impact is unclear. We developed the ALL Policy microsimulation model to estimate long-term clinical and economic outcomes for patients with pediatric ALL aged 0-17 in Ontario, Canada. We also illustrate the model’s clinical utility through a cost-effectiveness analysis of blinatumomab in relapsed B-cell ALL.
Methods
The ALL Policy model is informed using health administrative data and chart abstracted data from Ontario, Canada, and published literature. The model estimates lifetime risk of relapse, bone marrow transplant (BMT), conditional life expectancy, quality-adjusted life years (QALYs), and total health-care costs for individuals with pediatric ALL and can be stratified by relevant clinical characteristics (eg, B-cell or T-cell lineage). Additionally, we subset the model to patients with relapsed B-cell ALL to illustrate use of the model in estimating the cost-effectiveness of blinatumomab vs standard chemotherapy.
Results
Simulated pediatric ALL patients diagnosed from 2002 to 2012 had a projected conditional life expectancy of 64.90 years. The lifetime risk of BMT was estimated at 12.5%. Lifetime health-care costs were $244 433 Canadian Dollars (CAD) (95% confidence interval = $213 314 to $303 430). Treatment with blinatumomab compared to standard chemotherapy post-relapse was estimated to result in 1.08 additional QALYs and an additional cost of $59 410 CAD (incremental cost-effectiveness ratio of $54 885/QALY).
Conclusion
The ALL policy model can serve as a modeling foundation for timely economic evaluation. Introduction of blinatumomab in relapsed B-cell ALL may be a cost-effective strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON M5G0A4, Canada.
- Cancer Research Program, ICES, Toronto, ON M4N 3M5, Canada.
- Institute for Health Policy Evaluation and Management, University of Toronto, Toronto, Canada.
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON M561X8, Canada.
- Faculty of Medicine, University of Toronto, Toronto, Canada.
ORCID-Profile: Petros Pechlivanoglou, Sumit Gupta
Förderung
- Government of Ontario Early Research Award
Zitieren
APA
Pechlivanoglou, P., Luu, L., Li, Q., Rios, J. D., Moskalewicz, A., & Gupta, S. (2025). Development of a policy model for pediatric acute lymphoblastic leukemia to facilitate economic evaluation. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf024
Vancouver
Pechlivanoglou P, Luu L, Li Q, Rios JD, Moskalewicz A, Gupta S. Development of a policy model for pediatric acute lymphoblastic leukemia to facilitate economic evaluation. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf024
BibTeX
@article{Pechlivanoglou2025,
author = {Pechlivanoglou, Petros and Luu, Linda and Li, Qing and Rios, Juan David and Moskalewicz, Alexandra and Gupta, Sumit},
title = {Development of a policy model for pediatric acute lymphoblastic leukemia to facilitate economic evaluation},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djaf024}
}
EUVIMED